Triple
T22690614
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | BTK |
E561038
|
entity |
| Predicate | inhibitedBy |
P37861
|
FINISHED |
| Object |
spebrutinib
Spebrutinib is an experimental small-molecule Bruton’s tyrosine kinase (BTK) inhibitor being investigated primarily for the treatment of B-cell malignancies and autoimmune diseases.
|
E1549337
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: spebrutinib | Statement: [BTK, inhibitedBy, spebrutinib]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: spebrutinib Context triple: [BTK, inhibitedBy, spebrutinib]
-
A.
pirtobrutinib
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
E.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: spebrutinib Triple: [BTK, inhibitedBy, spebrutinib]
Generated description
Spebrutinib is an experimental small-molecule Bruton’s tyrosine kinase (BTK) inhibitor being investigated primarily for the treatment of B-cell malignancies and autoimmune diseases.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: spebrutinib Target entity description: Spebrutinib is an experimental small-molecule Bruton’s tyrosine kinase (BTK) inhibitor being investigated primarily for the treatment of B-cell malignancies and autoimmune diseases.
-
A.
pirtobrutinib
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
D.
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
E.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
- F. None of above. chosen
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454d71b48190a1f80af9f82b6fcf |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1789a1fd08190bce5fa0babe695d3 |
completed | April 29, 2026, 3:18 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a0b73fa5a648190b90ba303d1fe2397 |
completed | May 18, 2026, 8:18 p.m. |
| NEDg | Description generation | batch_6a0b7755eb048190ba1657a9a09bc24b |
completed | May 18, 2026, 8:32 p.m. |
| NED2 | Entity disambiguation (via description) | batch_6a0b780c0a4c8190b51b50c1e0e1a114 |
completed | May 18, 2026, 8:35 p.m. |
Created at: April 17, 2026, 3:13 p.m.